Agents targeting the Hedgehog pathway for pancreatic cancer treatment

Current Opinion in Investigational Drugs

Volumn 11, Issue 12, 2010, Pages 1387-1398

  Bisht, Savita ^a   Brossart, Peter ^a   Maitra, Anirban ^b   Feldmann, Georg ^a  

^a UNIVERSITY OF BONN   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclopamine; glioma associated oncogene homolog; Hedgehog signaling; mouse model; pancreatic cancer; small molecule inhibitor; Smoothened hedgehog; Sonic hedgehog; therapeutic target; translational research

Indexed keywords

2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; 3 KETO N AMINOETHYLAMINOCAPROYL DIGYROCINNAMOYL CYCLOPAMINE; ANTINEOPLASTIC AGENT; BMS 833923; CYCLOPAMINE; DASATINIB; DOXORUBICIN; ERLOTINIB; GANT 58; GANT 61; GEMCITABINE; IPI 609; IPI 611; IPI 926; N (3 METHOXYBENZYL) 3,3 DIMETHYL N [1 (3,4 METHYLENEDIOXYBENZYL) 2 (1 PIPERAZINYLCARBONYL) 4 PYRROLIDINYL]BUTYRAMIDE; PF 04449913; PURMORPHAMINE; ROBOTNIKININ; SOLASODINE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB; XL 139;

ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; GENE OVEREXPRESSION; HUMAN; LUNG SMALL CELL CANCER; LYMPHANGIOGENESIS; MEDULLOBLASTOMA; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOMATIC MUTATION; VERATRUM;

ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; HEDGEHOG PROTEINS; HUMANS; PANCREAS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79952768074     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Nusslein-Volhard C, Wieschaus E: Mutations affecting segment number and polarity in Drosophila. Nature (1980) 287(5785): 795-801. (Pubitemid 11214475)
2. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA: Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 425(6960):846-851. (Pubitemid 37351469)
3. Hidalgo M, Maitra A: The hedgehog pathway and pancreatic cancer. N Engl J Med (2009) 361(21):2094-2096.
4. Lees C, Howie S, Sartor RB, Satsangi J: The hedgehog signalling pathway in the gastrointestinal tract: Implications for development, homeostasis, and disease. Gastroenterology (2005) 129(5):1696-1710. (Pubitemid 41597408)
5. Maitra A, Hruban RH: Pancreatic cancer. Annu Rev Pathol (2008) 3:157-188. (Pubitemid 351488279)
6. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, Ouellette MM et al: Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut (2008) 57(10):1420-1430.
7. Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JB, Habbe N, Karikari C, Mullendore M, Gabrielson KL et al: An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 7(9):2725-2735.
8. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL et al: Blockade of Hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res (2007) 67(5):2187-2196. (Pubitemid 46424238)
9. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 324(5933):1457-1461.
10. Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, Garcia-Garcia E, Lopez-Rios F, Matsui W, Maitra A et al: A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 8(2):310-314.
11. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identifcation of pancreatic cancer stem cells. Cancer Res (2007) 67(3):1030-1037.
12. Rasheed ZA, Yang J, Wang Q, Freed I, Koorstra J-B, Hong S-M, He X, Berman D, Laheru D, Hidalgo M, Jimeno A et al: The functional stem cell marker aldehyde dehydrogenase enhances pancreatic cancer stem cell isolation and correlates with clinical prognosis. Annual Meeting of the American Association for Cancer Research (2008):Abs 5000.
13. Hruban RH, Klimstra DS, Pitman MB (Eds): Atlas of Tumor Pathology, Series IV. Tumors of the pancreas. Armed Forces Institute of Pathology, Washington DC, USA (2007).
14. Feldmann G, Maitra A: Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn (2008) 10(2):111-122. (Pubitemid 351428392)
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin (2008) 58(2):71-96.
16. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA et al: Pancreatic cancer. Curr Probl Cancer (2002) 26(4):176-275.
17. Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet (2004) 363(9414):1049-1057. (Pubitemid 38410779)
18. Ko AH, Tempero MA: Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw (2005) 3(5):627-636. (Pubitemid 44265411)
19. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer (2006) 94(4): 481-485. (Pubitemid 43289750)
20. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA (2007) 297(3): 267-277. (Pubitemid 46143304)
21. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 54(3):385-387. (Pubitemid 40299095)
22. Moore MJ: Brief communication: A new combination in the treatment of advanced pancreatic cancer. Semin Oncol (2005) 32(6 Suppl 8):5-6.
23. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F, Ruiz IAA: Melanomas require Hedgehog-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA (2007) 104(14):5895-5900. (Pubitemid 47175630)
24. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB: Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 422(6929):313-317. (Pubitemid 36378358)
25. Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, Memoli VA, Dmitrovsky E, Robbins DJ: Frequent requirement of Hedgehog signaling in non-small cell lung carcinoma. Oncogene (2007) 26(7):1046-1055.
26. Qualtrough D, Buda A, Gaffeld W, Williams AC, Paraskeva C: Hedgehog signalling in colorectal tumour cells: Induction of apoptosis with cyclopamine treatment. Int J Cancer (2004) 110(6):831-837. (Pubitemid 38758508)
27. Oniscu A, James RM, Morris RG, Bader S, Malcomson RD, Harrison DJ: Expression of sonic hedgehog pathway genes is altered in colonic neoplasia. J Pathol (2004) 203(4):909-917. (Pubitemid 39089279)
28. Monzo M, Moreno I, Artells R, Ibeas R, Navarro A, Moreno J, Hernandez R, Granell M, Pie J: Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett (2006) 233(1):117-123. (Pubitemid 43214569)
29. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 431(7009):707-712. (Pubitemid 39382619)
30. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, Beyna M, Datta MW, Datta S, Ruiz i Altaba A: Inhibition of prostate cancer proliferation by interference with Sonic hedgehog-GLI1 signaling. Proc Natl Acad Sci USA (2004) 101(34):12561-12566. (Pubitemid 39122063)
31. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther (2006) 5(6):674-683. (Pubitemid 44024723)
32. Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, Zhang K, Tang W, Stelter AA, Wang Q, Zhang H et al: Activation of the Hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis (2006) 27(7):1334-1340. (Pubitemid 43985408)
33. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A, Feldmann G: Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res (2009) 15(7):2291-2301.
34. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B et al: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 425(6960) 51-856.
35. Rubin LL, de Sauvage FJ: Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5(12):1026-1033. (Pubitemid 44835129)
36. Ball DW, Leach SD: Notch in malignancy. Cancer Treat Res (2003) 115:95-121.
37. Hahn H, Christiansen J, Wicking C, Zaphiropoulos PG, Chidambaram A, Gerrard B, Vorechovsky I, Bale AE, Toftgard R, Dean M, Wainwright B: A mammalian patched homolog is expressed in target tissues of Sonic hedgehog and maps to a region associated with developmental abnormalities. J Biol Chem (1996) 271(21):12125-12128. (Pubitemid 26160866)
38. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, Quinn AG, Myers RM, Cox DR, Epstein EH Jr, Scott MP: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science (1996) 272(5268):1668-1671. (Pubitemid 26200029)
39. Epstein EH: Basal cell carcinomas: Attack of the Hedgehog. Nat Rev Cancer (2008) 8(10):743-754.
40. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, James CD: Sporadic medulloblastomas contain PTCH mutations. Cancer Res (1997) 57(5):842-845. (Pubitemid 27098006)
41. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sorensen N, Berthold F, Henk B, Schmandt N, Wolf HK et al: Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res (1997) 57(11):2085-2088. (Pubitemid 27247016)
42. Vorechovsky I, Tingby O, Hartman M, Stromberg B, Nister M, Collins VP, Toftgard R: Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene (1997) 15(3):361-366. (Pubitemid 27370882)
43. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A et al: Mutations in SUFU predispose to medulloblastoma. Nat Genet (2002) 31(3):306-310.
44. Zhang X, Harrington N, Moraes RC, Wu MF, Hilsenbeck SG, Lewis MT: Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (SMO). Breast Cancer Res Treat (2009) 115(3):505-521.
45. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M et al: A paracrine requirement for Hedgehog signalling in cancer. Nature (2008) 455(7211):406-410.
46. Sasai K, Romer JT, Lee Y, Finkelstein D, Fuller C, McKinnon PJ, Curran T: SHH pathway activity is down-regulated in cultured medulloblastoma cells: Implications for preclinical studies. Cancer Res (2006) 66(8):4215-4222.
47. Becher OJ, Hambardzumyan D, Fomchenko EI, Momota H, Mainwaring L, Bleau AM, Katz AM, Edgar M, Kenney AM, Cordon-Cardo C, Blasberg RG et al: GLI activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res (2008) 68(7):2241-2249. (Pubitemid 351521797)
48. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH et al: Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 137(3):1102-1113.
49. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M et al: Prognostic signifcance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 102(5):340-351.
50. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV, Hidalgo M et al: Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 7(3):279-282.
51. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA: Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res (2008) 14(19):5995-6004.
52. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M: Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev (2006) 20(22):3161-3173. (Pubitemid 44790630)
53. Ji Z, Mei FC, Xie J, Cheng X: Oncogenic Kras activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem (2007) 282(19):14048-14055. (Pubitemid 47100411)
54. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 321(5897):1801-1806.
55. Scales SJ, de Sauvage FJ: Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci (2009) 30(6):303-312.
56. Ericson J, Morton S, Kawakami A, Roelink H, Jessell TM: Two critical periods of Sonic hedgehog signaling required for the specifcation of motor neuron identity. Cell (1996) 87(4):661-673. (Pubitemid 26386940)
57. Bailey JM, Mohr AM, Hollingsworth MA: Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene (2009) 28(40):3513-3525.
58. Nakamura M, Kubo M, Yanai K, Mikami Y, Ikebe M, Nagai S, Yamaguchi K, Tanaka M, Katano M: Anti-patched-1 antibodies suppress Hedgehog signaling pathway and pancreatic cancer proliferation. Anticancer Res (2007) 27(6A):3743-3747. (Pubitemid 47598439)
59. Sinha S, Chen JK: Purmorphamine activates the Hedgehog pathway by targeting Smoothened. Nat Chem Biol (2006) 2(1): 29-30.
60. Stanton BZ, Peng LF, Maloof N, Nakai K, Wang X, Duffner JL, Taveras KM, Hyman JM, Lee SW, Koehler AN, Chen JK et al: A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol (2009) 5(3):154-156.
61. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA: Small molecule modulation of Smoothened activity. Proc Natl Acad Sci USA (2002) 99(22):14071-14076. (Pubitemid 35257626)
62. Binns W, James LF, Shupe JL, Everett G: A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, Veratrum californicum. Am J Vet Res (1963) 24:1164-1175.
63. Keeler RF, Binns W: Teratogenic compounds of veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources. Teratology (1968) 1(1):5-10.
64. Cooper MK, Porter JA, Young KE, Beachy PA: Teratogen-mediated inhibition of target tissue response to SHH signaling. Science (1998) 280(5369):1603-1607. (Pubitemid 28277705)
65. Brian A, Janardannair S, Lescarbeau A, Tremblay M, Grayzel D, Matsui W: Methods of use of cyclopamine analogs. WO-2008083252 (2008).
66. Tremblay MR, Nevalainen M, Nair SJ, Porter JR, Castro AC, Behnke ML, Yu LC, Hagel M, White K, Faia K, Grenier L et al: Semisynthetic cyclopamine analogues as potent and orally bioavailable Hedgehog pathway antagonists. J Med Chem (2008) 51(21):6646-6649.
67. Wilson SR, Strand MF, Krapp A, Rise F, Petersen D, Krauss S: Hedgehog antagonist cyclopamine isomerizes to less potent forms when acidifed. J Pharm Biomed Anal (2010) 52(5): 707-713.
68. Incardona JP, Gaffeld W, Lange Y, Cooney A, Pentchev PG, Liu S, Watson JA, Kapur RP, Roelink H: Cyclopamine inhibition of Sonic hedgehog signal transduction is not mediated through effects on cholesterol transport. Dev Biol (2000) 224(2):440-452. (Pubitemid 30661023)
69. Beachy PA: Regulators of the hedgehog pathway, compositions and uses related thereto. WO-01027135 (2001).
70. Siegelin MD, Siegelin Y, Habel A, Rami A, Gaiser T: KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway. Neurobiol Dis (2009) 34(2): 259-266.
71. Ma X, Sheng T, Zhang Y, Zhang X, He J, Huang S, Chen K, Sultz J, Adegboyega PA, Zhang H, Xie J: Hedgehog signaling is activated in subsets of esophageal cancers. Int J Cancer (2006) 118(1):139-148 (Pubitemid 41681590)
72. Synthesis of novel, chemically stable d-homo-cyclopamine analogs via a cyclopropanation/ring-expansion sequence: Infnity Pharmaceuticals, Cambridge, MA, USA (2007). www.inf.com/pipelinearchives/GRC%202007%20INFI%20Hh%20Poster.pdf
73. Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC, Yu LC, Behnke ML, Nair SJ, Hagel M, White K et al: Discovery of a potent and orally active Hedgehog pathway antagonist (IPI-926). J Med Chem (2009) 52(14):4400-4418.
74. Katoh Y, Katoh M: Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med (2009) 9(7):873-886.
75. Pink M, Proctor J, Briggs K, MacDougall J, Whitebread N, Tremblay M, Grogan MJ, Palombella V, Castro A, Adams J, Read M et al: Activity of IPI-926, a potent HH pathway inhibitor, in a novel model of medulloblastoma derived from Ptch/HIC +/-mice. Annual Meeting of the American Association of Cancer Research, San Diego, CA, USA (2008):Abs 1588.
76. Infnity Pharmaceuticals: Infnity initiates randomized clinical trial of IPI-926 in pancreatic cancer and reports new preclinical data at AACR. Press Release (2010): April 21. investor.inf.com/releasedetail.cfm?ReleaseID=461797
77. Zhang J, Garrossian M, Gardner D, Garrossian A, Chang YT, Kim YK, Chang CW: Synthesis and anticancer activity studies of cyclopamine derivatives. Bioorg Med Chem Lett (2008) 18(4):1359-1363. (Pubitemid 351226541)
78. Kumar SK, Roy I, Anchoori RK, Fazli S, Maitra A, Beachy PA, Khan SR: Targeted inhibition of Hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg Med Chem (2008) 16(6):2764-2768. (Pubitemid 351444824)
79. Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, Gatchalian C, Porter JA, Rubin LL, Wang FY: Identifcation of a small molecule inhibitor of the Hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA (2003) 100(8):4616-4621. (Pubitemid 36457779)
80. Curis Inc: Curis provides update on basal cell carcinoma phase I clinical trial; parties determine to halt phase I trial. Press Release (2006):July 11.
81. Rubin L, Guicherit OM, Price S, Boyd EA: Mediators of Hedgehog signaling pathways, composition and uses related thereto. WO-03011219 (2003).
82. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T: Suppression of the SHH pathway using a small molecule inhibitor eliminates medulloblastoma in ptc1p53 mice. Cancer Cell (2004) 6(3):229-240. (Pubitemid 39222036)
83. Sasai K, Romer JT, Kimura H, Eberhart DE, Rice DS, Curran T: Medulloblastomas derived from CXCR6 mutant mice respond to treatment with a Smoothened inhibitor. Cancer Res (2007) 67(8):3871-3877. (Pubitemid 46762175)
84. Kimura H, Ng JM, Curran T: Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell (2008) 13(3):249-260. (Pubitemid 351324879)
85. Peukert S, Jain RK, Geisser A, Sun Y, Zhang R, Bourret A, Carlson A, Dasilva J, Ramamurthy A, Kelleher JF: Identifcation and structure-activity relationships of ortho-biphenyl carboxamides as potent smoothened antagonists inhibiting the Hedgehog signaling pathway. Bioorg Med Chem Lett (2009) 19(2):328-331.
86. Novartis AG (Jain RK, Kelleher J, Peukert S, Sun Y): Use of biarylcarboxamides in the treatment of Hedgehog pathway-related disorders WO-2007120827 (2007).
87. IRM LLC (Gao W, Jiang J, Wan Y, Cheng D, Han D, Wu X, Pan S): Compounds and compositions as Hedgehog pathway modulators. WO-2007131201 (2007).
88. Curis Inc; Genentech Inc (Goldsmith RA, Sutherlin DA, Robarge KD, Olivero AG): Bisamide inhibitors of Hedgehog signaling. WO-2007059157 (2007).
89. Novartis AG (Dai M, He F, Jain RK, Karki R, Kelleher J, Lei J, Llamas L, Mcewan MA, Miller-Moslin K, Perez LA, Peukert S et al): Organic compounds and their uses. WO-2008110611 (2008).
90. Rominger CM, Bee WL, Copeland RA, Davenport EA, Gilmartin A, Gontarek R, Hornberger KR, Kallal LA, Lai Z, Lawrie K, Lu Q et al: Evidence for allosteric interactions of antagonist binding to the Smoothened receptor. J Pharmacol Exp Ther (2009) 329(3):995-1005.
91. Buttner A, Seifert K, Cottin T, Sarli V, Tzagkaroulaki L, Scholz S, Giannis A: Synthesis and biological evaluation of SANT-2 and analogues as inhibitors of the Hedgehog signaling pathway. Bioorg Med Chem (2009) 17(14):4943-4954.
92. Remsberg JR, Lou H, Tarasov SG, Dean M, Tarasova NI: Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. J Med Chem (2007) 50(18):4534-4538. (Pubitemid 47378850)
93. Tremblay MR, Nesler M, Weatherhead R, Castro AC: Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Pat (2009) 19(8):1039-1056.
94. Walker K, Padhiar M: AACR-NCI-EORTC-21st International Symposium. Molecular targets and cancer therapeutics-Part 1. IDrugs (2010) 13(1):7-9.
95. Svard J, Heby-Henricson K, Persson-Lek M, Rozell B, Lauth M, Bergstrom A, Ericson J, Toftgard R, Teglund S: Genetic elimination of suppressor of fused reveals an essential repressor function in the mammalian hedgehog signaling pathway. Dev Cell (2006) 10(2):187-197. (Pubitemid 43174952)
96. Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, Curran T, McKinnon PJ: Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene (2007) 26(44):6442-6447. (Pubitemid 47494220)
97. Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Masuelli L, Napolitano M, Maroder M, Modesti A et al: REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci USA (2004) 101(29):10833-10838. (Pubitemid 38955828)
98. Argenti B, Gallo R, Di Marcotullio L, Ferretti E, Napolitano M, Canterini S, De Smaele E, Greco A, Fiorenza MT, Maroder M, Screpanti I et al: Hedgehog antagonist REN(KCTD11) regulates proliferation and apoptosis of developing granule cell progenitors. J Neurosci (2005) 25(36):8338-8346. (Pubitemid 41292129)
99. Ruiz I, Altaba A, Mas C, Stecca B: The GLI code: An information nexus regulating cell fate, stemness and cancer. Trends Cell Biol (2007) 17(9):438-447. (Pubitemid 47505310)
100. Bian YH, Huang SH, Yang L, Ma XL, Xie JW, Zhang HW: Sonic hedgehog-GLI1 pathway in colorectal adenocarcinomas. World J Gastroenterol (2007) 13(11):1659-1665. (Pubitemid 46711335)
101. Kimura H, Stephen D, Joyner A, Curran T: GLI1 is important for medulloblastoma formation in Ptc1 mice. Oncogene (2005) 24(25):4026-4036. (Pubitemid 40897050)
102. Goyette P, Allan D, Peschard P, Chen CF, Wang W, Lohnes D: Regulation of GLI activity by all-trans retinoic acid in mouse keratinocytes. Cancer Res (2000) 60(19):5386-5389.
103. Bhatia N, Thiyagarajan S, Elcheva I, Saleem M, Dlugosz A, Mukhtar H, Spiegelman VS: GLI2 is targeted for ubiquitination and degradation by β-TrCP ubiquitin ligase. J Biol Chem (2006) 281(28):19320-19326. (Pubitemid 44035437)
104. Lauth M, Bergstrom A, Shimokawa T, Toftgard R: Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA (2007) 104(20):8455-8460. (Pubitemid 47175509)
105. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM et al: Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 361(12):1164-1172.
106. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM et al: Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 361(12):1173-1178.
107. Kean S: Medicine. Disrupting hedgehog may reverse advanced cancer, if only temporarily. Science (2009) 325(5945):1188.
108. Mahindroo N, Punchihewa C, Fujii N: Hedgehog-GLI signaling pathway inhibitors as anticancer agents. J Med Chem (2009) 52(13):3829-3845.
109. Stanton BZ, Peng LF: Small-molecule modulators of the Sonic hedgehog signaling pathway. Mol Biosyst (2010) 6(1): 44-54.
110. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF et al: Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 326(5952):572-574.